|
| Press Releases |
|
 |
|
| Thursday, December 19, 2019 |
|
|
Viva Biotech Was Included as a Constituent Stock of the Hang Seng Hong Kong-Listed Biotech Index |
| Viva Biotech Holdings ("Viva Biotech" or the "Company"; stock code: 1873.HK), the world leading operator of a structure-based drug discovery (SBDD) platform, is included as a constituent stock of the Hang Seng Hong Kong-Listed Biotech Index. more info >> |
|
| Monday, October 14, 2019 |
|
|
Cheney Mao - Chairman & CEO, Viva Biotech, China |
| Dr Cheney Mao, chairman and CEO of Viva Biotech, shares the extremely unique business model of the company, which started as a highly specialized CRO in 2008, before launching a new 'equity-for-service' model in 2016 that focused on incubating biotech start-ups from their inception to IND stage. more info >> |
|
| Friday, August 30, 2019 |
|
|
摩通看好維亞生物 目標價5.5港元 |
| 港股近期不少半新股正在熱身，而績優股更持續見強勢。維亞生物(1873)最近公布了中期業績，符合預期。 more info >> |
|
| Thursday, August 22, 2019 |
|
|
安捷证券：首次覆盖维亚生物 (1873.HK)给予买入评级，目标价5.03港元 |
在未来中国医药市场中，创新能力决定着企业的定价能力和竞争力。随着药企出于成本控制和效率提升考虑而更多地使用外包服务，我们认为中国药物发现CRO行业迎来了增长的黄金时期。
more info >> |
|
|
安捷證券：首次覆蓋維亞生物 (1873.HK)給予買入評級，目標價5.03港元 |
在未來中國醫藥市場中，創新能力決定著企業的定價能力和競爭力。隨著藥企出於成本控制和效率提升考慮而更多地使用外包服務，我們認為中國藥物發現CRO行業迎來了增長的黃金時期。
more info >> |
|
| Wednesday, July 3, 2019 |
|
|
維亞生物孵化企業Dogma揭秘首創口服PCSK9抑制劑研發項目 |
维亚生物科技控股集团（「維亞生物」或「公司」連同其附屬公司，統稱「集團」或「維亞生物集團」；股份代號：1873.HK），全球領先的基於結構的新藥發現（「SBDD」）技術平台營運商，今天欣然宣佈，其孵化企業Dogma Therapeutics（「Dogma」）公開了其口服PCSK9抑制劑研發項目，該項目通過和Charles River及維亞生物的獨特合作模式加速了研發進展速度。
more info >> |
|
| Thursday, April 25, 2019 |
|
|
维亚生物宣布于港交所主板上市计划 |
维亚生物科技控股集团（维亚生物」或「公司」连同其附属公司，统称「集团」或「维亚生物集团」；股份代号： 1873.HK），按2018年收入及2018年同步辐射波束时间计，领先的基于结构的新药发现技术平台营运商，今天宣布于香港联合交易所有限公司（「联交所」）主板上市计划。
more info >> |
|
|
維亞生物宣佈於港交所主板上市計劃 |
维亚生物科技控股集团（維亞生物」或「公司」連同其附屬公司，統稱「集團」或「維亞生物集團」；股份代號：1873.HK），按2018年收入及2018年同步輻射波束時間計，領先的基於結構的新藥發現技術平台營運商，今天宣佈於香港聯合交易所有限公司（「聯交所」）主板上市計劃。
more info >> |
|
|
Viva Biotech Announces Proposed Listing on the Main Board of SEHK |
Viva Biotech Holdings ("Viva Biotech" or the "Company", together with its subsidiaries, the "Group" or "Viva Biotech Group"; stock code: 1873.HK), a leading structure-based, integrated drug discovery platform operator in terms of revenue in 2018 and beam time for synchrotron radiation in 2018, announced the proposed listing of its shares on the Main Board of The Stock Exchange of Hong Kong Limited ("SEHK") today.
more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Fujitsu and 1Finity to highlight latest network technologies and AI solutions at MWC Barcelona 2026
Feb 13, 2026 22:50 JST
|
|
|
Fujitsu to present latest technologies for creating social and industrial value through fusion of AI and computing at India AI Impact Summit 2026
Feb 13, 2026 22:33 JST
|
|
|
Mitsubishi Power Hosts Inaugural Energy Forward Forum in Indonesia with Government and Industry Experts
Feb 13, 2026 22:24 JST
|
|
|
MHI Successfully Demonstrates Production of Liquid Synthetic Fuels through an integrated Process Utilizing SOEC Co-Electrolysis and FT Synthesis
Feb 13, 2026 22:03 JST
|
|
|
天瞳威視J6B方案斬獲上海知名車企近百萬量產定點：20TOPS算力已破局？
Feb 13, 2026 19:14 HKT/SGT
|
|
|
天瞳威视J6B方案斩获上海知名车企近百万量产定点：20TOPS算力已破局？
Feb 13, 2026 18:41 HKT/SGT
|
|
|
JCB Sponsors the NHK Symphony Orchestra Singapore Concert 2026 - Celebrating 60 Years of Singapore-Japan Relations
Feb 13, 2026 14:00 JST
|
|
|
現代牙科集團四十週年誌慶：「數字驅動 重塑笑容新標準」
Feb 13, 2026 10:36 HKT/SGT
|
|
|
Modern Dental Group Celebrates 40 Years: 'Redefining Smiles. The Digital Way.'
Feb 13, 2026 10:31 HKT/SGT
|
|
|
GA-ASI 實現半自主 CCA 飛行新里程碑
Feb 13, 2026 10:30 HKT/SGT
|
|
|
GA-ASI 实现半自主 CCA 飞行新里程碑
Feb 13, 2026 10:30 HKT/SGT
|
|
|
现代牙科集团四十周年志庆：「数字驱动 重塑笑容新标准」
Feb 13, 2026 09:40 HKT/SGT
|
|
|
GA-ASI Achieves New Milestone With Semi-Autonomous CCA Flight
Feb 13, 2026 07:00 HKT/SGT
|
|
|
Open World and VerifyMe Sign Merger Agreement
Feb 12, 2026 21:00 HKT/SGT
|
|
|
U.S. Polo Assn. 於 USPA 國家馬球中心推出全新沉浸式 USPA Shop 旗艦店
Feb 12, 2026 20:00 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
